Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.

摘要: Summary Background Virulent Bordetella pertussis, the causative agent of whooping cough, exacerbates allergic airway inflammation in a murine model ovalbumin (OVA) sensitization. A live genetically attenuated B. pertussis mucosal vaccine, BPZE1, has been developed that evokes full protection against virulent challenge mice but effect this strain on development responses is unknown. Objective To assess influence BPZE1 OVA priming inflammation. Methods Mice were challenged with or strains and sensitized to allergen at peak bacterial carriage. Subsequently, pathology, local OVA-specific immunity examined. Results In contrast did not exacerbate reduced pathology associated immunization before sensitization have an adjuvant specific IgE resulted statistically significant decrease tissue bronchoalveolar lavage fluid. significantly levels OVA-driven IL-4, IL-5 IL-13 induced increase IFN-γ response re-stimulation. Conclusions These data demonstrate that, unlike strains, candidate vaccine does allergen-driven pathology. may represent attractive T-helper type 1 promoting for eradication cough unlikely promote atopic disease.